All Relations between Tuberous Sclerosis and mtor

Publication Sentence Publish Date Extraction Date Species
Saygın Yıldırım, Ebru Aypar, Burça Aydın, Canan Akyüz, Hayrettin Hakan Aykan, İlker Ertuğrul, Tevfik Karagöz, Dursun Aleha. Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment. The Turkish journal of pediatrics. vol 65. issue 3. 2023-07-03. PMID:37395967. everolimus, a mechanistic target of rapamycin (mtor) inhibitor, can be used in the treatment of rhabdomyomas seen in tuberous sclerosis complex. 2023-07-03 2023-08-14 Not clear
Simone Bonazzi, Audrey Gray, Noel M Thomsen, Jonathan Biag, Nancy Labbe-Giguere, Erin P Keaney, Hasnain A Malik, Yingchuan Sun, Jill Nunez, Rajeshri G Karki, Mark Knapp, Robert Elling, John Fuller, Gwynn Pardee, Lucas Craig, Ketthsy Capre, Sarah Salas, Aakruti Gorde, Guiqing Liang, Danuta Lubicka, Stephanie M McTighe, Carleton Goold, Shanming Liu, Lin Deng, Jin Hong, Alexander Fekete, Pascal Stadelmann, Wilfried Frieauff, Azeddine Elhajouji, Daniel Bauer, Andreas Lerchner, Branko Radetich, Pascal Furet, Grazia Piizzi, Doug Burdette, Christopher J Wilson, Stefan Peukert, Lawrence G Hamann, Leon O Murphy, Daniel Curti. Identification of Brain-Penetrant ATP-Competitive mTOR Inhibitors for CNS Syndromes. Journal of medicinal chemistry. 2023-07-03. PMID:37399505. the allosteric inhibitor of the mechanistic target of rapamycin (mtor) everolimus reduces seizures in tuberous sclerosis complex (tsc) patients through partial inhibition of mtor functions. 2023-07-03 2023-08-14 Not clear
Aishwarya Ramamurthy, Gemma Louise Carvil. Raptor Preys on mTOR Imbalance in Tuberous Sclerosis. Epilepsy currents. vol 23. issue 3. 2023-06-19. PMID:37334409. raptor preys on mtor imbalance in tuberous sclerosis. 2023-06-19 2023-08-14 Not clear
Elisabetta Chiaradia, Ingrid Miller, Giovanni Renzone, Alessia Tognoloni, Alice Polchi, Federico De Marco, Brunella Tancini, Andrea Scaloni, Alessandro Magin. Proteomic analysis of murine Tsc1-deficient neural stem progenitor cells. Journal of proteomics. 2023-05-19. PMID:37207814. significance: tuberous sclerosis complex (tsc) is a multisystemic disorder caused by inactivating mutations of tsc1 or tsc2 genes, which induce overactivation of the mtor component. 2023-05-19 2023-08-14 Not clear
Uchenna Unachukwu, Jarrod Sonett, Denzel Woode, Takayuki Shiomi, Kiran Chada, Jeanine M D'Armient. Tyrosine Kinase Inhibitors Diminish Renal Neoplasms in a Tuberous Sclerosis Model via induction of Apoptosis. Molecular cancer therapeutics. 2023-05-01. PMID:37127876. tuberous sclerosis complex (tsc) tumors are presently incurable despite a cytostatic response to mtor pathway inhibition since recurrence of disease occurs after discontinuation of treatment. 2023-05-01 2023-08-14 mouse
Dominika Śmiałek, Katarzyna Kotulska, Aleksandra Duda, Sergiusz Jóźwia. Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age. Neurology and therapy. 2023-04-21. PMID:37085686. effect of mtor inhibitors in epilepsy treatment in children with tuberous sclerosis complex under 2 years of age. 2023-04-21 2023-08-14 Not clear
Dominika Śmiałek, Katarzyna Kotulska, Aleksandra Duda, Sergiusz Jóźwia. Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age. Neurology and therapy. 2023-04-21. PMID:37085686. mechanistic target of rapamycin (mtor) inhibitors sirolimus and everolimus are an effective therapy for subependymal giant cell astrocytomas, cardiac rhabdomyomas, renal angiomyolipomas, and lymphangioleiomyomatosis associated with tuberous sclerosis complex (tsc). 2023-04-21 2023-08-14 Not clear
Lijun Lv, Jiyu Guan, Ruixue Zhen, Pin Lv, Mengshi Xu, Xingyuan Liu, Shishi He, Ziyu Fang, Zi Li, Yungang Lan, Huijun Lu, Wenqi He, Feng Gao, Kui Zha. Orf virus induces complete autophagy to promote viral replication via inhibition of AKT/mTOR and activation of the ERK1/2/mTOR signalling pathway in OFTu cells. Veterinary research. vol 54. issue 1. 2023-03-15. PMID:36918891. moreover, orfv-induced autophagic activity was found to rely on an increase in the phosphorylation of tuberous sclerosis complex 2 (tsc2) and a decrease in the phosphorylation of mammalian target of rapamycin (mtor), which is mediated by the suppression of the pi3k/akt/mtor signalling pathway and activation of the erk1/2/mtor signalling pathway. 2023-03-15 2023-08-14 Not clear
S Auvin, S Baula. mTOR-therapy and targeted treatment opportunities in mTOR-related epilepsies associated with cortical malformations. Revue neurologique. 2023-03-11. PMID:36906459. mutations of mtor pathway genes are involved in tuberous sclerosis complex (tsc) as well as in a range of cortical malformations from hemimegalencephaly (hme) to type ii focal cortical dysplasia (fcd ii), leading to the concept of "mtoropathies" (mtor pathway-related malformations). 2023-03-11 2023-08-14 mouse
Seth Bernacki, Paarth Dodia, Mikél Elizabeth Muse, Luke Maxfiel. Cutaneous Manifestations of Sarcoidosis Seen in a Patient with a History of Tuberous Sclerosis. Case reports in dermatology. vol 15. issue 1. 2023-02-23. PMID:36817851. there may be a shared dysfunction of mtor present in sarcoidosis and tuberous sclerosis. 2023-02-23 2023-08-14 Not clear
Dominika Śmiałek, Sergiusz Jóźwiak, Katarzyna Kotulsk. Safety of Sirolimus in Patients with Tuberous Sclerosis Complex under Two Years of Age-A Bicenter Retrospective Study. Journal of clinical medicine. vol 12. issue 1. 2023-01-08. PMID:36615165. mtor inhibitors are a novel pharmacotherapy recommended for subependymal giant astrocytomas, refractory epilepsy, and the treatment of the other clinical manifestations of tuberous sclerosis complex (tsc). 2023-01-08 2023-08-14 Not clear
D Farges, N Sigg, D Ville, L Marti. Use of mTOR inhibitors (rapalogs) for the treatment of skin changes in tuberous sclerosis complex. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie. vol 29. issue 5S. 2022-12-30. PMID:36585067. use of mtor inhibitors (rapalogs) for the treatment of skin changes in tuberous sclerosis complex. 2022-12-30 2023-08-14 Not clear
Kuriko Kagitani-Shimono, Hiroki Kato, Fumihiko Soeda, Yoshiko Iwatani, Masashi Mukai, Katsuhiro Ogawa, Koji Tominaga, Shin Nabatame, Masako Taniik. Extension of microglial activation is associated with epilepsy and cognitive dysfunction in Tuberous sclerosis complex: A TSPO-PET study. NeuroImage. Clinical. vol 37. 2022-12-15. PMID:36521371. tuberous sclerosis complex (tsc) is a condition that results in the overactivation of the mammalian target of rapamycin (mtor) pathway, which has been linked to the activation of microglia responsible for neuroinflammation. 2022-12-15 2023-08-14 Not clear
Chen-Xi Zhang, Kai-Feng Xu, Qin Long, Xiao Zhang, Zhi-Kun Yang, Rong-Ping Dai, Zhi-Qiao Zhan. Long-term efficacy and safety of sirolimus for retinal astrocytic hamartoma associated with tuberous sclerosis complex. Frontiers in cell and developmental biology. vol 10. 2022-12-05. PMID:36467422. mammalian target of rapamycin (mtor) inhibitors (sirolimus or everolimus) have been demonstrated effective in reducing the size of tuberous sclerosis complex (tsc)-associated retinal astrocytic hamartoma (rah) in short term. 2022-12-05 2023-08-14 Not clear
Shengzhao Hu, Yingli Chen, Shipeng Huang, Min Liu, Ying Liu, Shaofang Huan. Sodium Danshensu protects against oxygen glucose deprivation/reoxygenation-induced astrocytes injury through regulating NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome and tuberous sclerosis complex-2 (TSC2)/mammalian target of rapamycin (mTOR) pathways. Annals of translational medicine. vol 10. issue 20. 2022-11-17. PMID:36388798. sodium danshensu protects against oxygen glucose deprivation/reoxygenation-induced astrocytes injury through regulating nod-like receptor pyrin domain containing 3 (nlrp3) inflammasome and tuberous sclerosis complex-2 (tsc2)/mammalian target of rapamycin (mtor) pathways. 2022-11-17 2023-08-14 Not clear
Molly C McNamara, Aaron M Hosios, Margaret E Torrence, Ting Zhao, Cameron Fraser, Meghan Wilkinson, David J Kwiatkowski, Elizabeth P Henske, Chin-Lee Wu, Kristopher A Sarosiek, Alexander J Valvezan, Brendan D Mannin. Reciprocal effects of mTOR inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complex. iScience. vol 25. issue 11. 2022-11-17. PMID:36388985. reciprocal effects of mtor inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complex. 2022-11-17 2023-08-14 Not clear
Kate Mowrey, Hope Northrup, Syed Shahrukh Hashmi, David Rodriguez-Buritic. Expanding Our Knowledge of Menstrual Irregularities Reported by Females With Tuberous Sclerosis Complex. Frontiers in reproductive health. vol 4. 2022-10-28. PMID:36303615. the purpose of our study is to expand the knowledge regarding intrinsic reproductive dysfunction in females with tsc and to explore the impact of mtor inhibitors (mtori) on menstrual irregularity in the tuberous sclerosis complex (tsc) community. 2022-10-28 2023-08-14 Not clear
R Balestri, L Rizzoli, A Pedrolli, Sam Urru, G Rech, I Neri, C R Girardelli, M Magnan. Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in Tuberous Sclerosis Complex - An Update. Journal of the European Academy of Dermatology and Venereology : JEADV. 2022-10-27. PMID:36300771. analysis of current data on the use of topical mtor inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex - an update. 2022-10-27 2023-08-14 human
Marie Girodengo, Sila K Ultanir, Joseph M Batema. Mechanistic target of rapamycin signaling in human nervous system development and disease. Frontiers in molecular neuroscience. vol 15. 2022-10-13. PMID:36226315. mtor signaling has a well-established role in hamartoma syndromes such as tuberous sclerosis complex (tsc) and other mtoropathies. 2022-10-13 2023-08-14 human
Jingwen Zhan. Systematic review of mTOR inhibitor treatment, biomarkers and prophylaxis for tuberous sclerosis complex-associated seizures. Clinical medicine (London, England). vol 22. issue Suppl 4. 2022-10-11. PMID:36220212. systematic review of mtor inhibitor treatment, biomarkers and prophylaxis for tuberous sclerosis complex-associated seizures. 2022-10-11 2023-08-14 Not clear